Entries by Melanie Piontek

ARTES attends Biofit 2017

Meet us at the Biofit 2017 tak­ing place in Stras­bourg Novem­ber 28 -29. Michael Pio­ntek, Man­ag­ing Direc­tor at ARTES, will be present in the One-on-One Part­ner­ing and we are present with our own booth (num­ber F2). Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a notice via the part­ner­ing sys­tem. We look […]

ARTES receives French Research Tax Credit (CIR) Accreditation

ARTES Biotech­nol­o­gy GmbH today announced that it has just obtained gov­ern­men­tal approval for ‘Crédit d’Impôt Recherche’ (CIR) for a three-year peri­od from the French Min­istry of High­er Edu­ca­tion and Research (MESR). The French R&D tax cred­it CIR gives French com­pa­nies the abil­i­ty to claim tax relief on 30% on all gen­er­at­ed costs out­sourced to ARTES’ […]

ARTES was part of a successful international consortium

EU Research Project Nano3Bio sums up: Promis­ing achieve­ments for win­ning future raw mate­ri­als Since fos­sil raw mate­ri­als are rapid­ly run­ning out, their sub­sti­tu­tion by renew­able resources is becom­ing increas­ing­ly impor­tant. In this process, the bio­log­i­cal pro­duc­tion of raw mate­ri­als will have to play a lead­ing role. The inter­na­tion­al project Nano3Bio, includ­ing ARTES Biotech­nol­o­gy has con­tributed […]

ARTES received next grant of patent for METAVAX®

ARTES is pleased to announce a new EU based grant of patent for their well-proven virus-like-par­ti­­cle (VLP) tech­nol­o­gy plat­form METAVAX®. “The new patent inte­grates exact­ly in our exist­ing patent port­fo­lio and will fur­ther strength­en our tech­nol­o­gy offer”, said Dr. Melanie Pio­ntek, Busi­ness Devel­op­ment Direc­tor of ARTES. “In com­bi­na­tion with our pro­pri­etary yeast expres­sion tech­nol­o­gy our […]


A con­sor­tium of 5 com­pa­nies and the Fraun­hofer-Insti­­tut für Lasertech­nik ILT, aim to devel­op under the name of WAVESCATTER („Winke­lau­flösende Wellen­leit­er-Streulicht­­sonde für die Inline-Prozes­s­an­a­­lytik“) a new kind of scat­tered light sen­sor for pre­cise inline par­ti­cle ana­lyt­ic. The project will be fund­ed for a three year peri­od by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research […]

BIO International Convention 2017

Meet us at the BIO Inter­na­tion­al Con­ven­tion tak­ing place in San Diego, CA, USA  June 19 -22. Michael Pio­ntek, Man­ag­ing Direc­tor at ARTES, will be present in the One-on-One Part­ner­ing. Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a notice via the part­ner­ing sys­tem. We look for­ward to meet­ing you!   www.convention.bio.org/2017

15 Years ARTES Biotechnology

Toady, ARTES has 15 year anniver­sary. In 2002 at May 10th Michael Pio­ntek found­ed ARTES as R&D com­pa­ny, spe­cial­ized in devel­op­ing yeast cell lines for recom­bi­nant pro­tein pro­duc­tion. In 15 years ARTES has posi­tioned itself as val­ued part­ner for the phar­ma­ceu­ti­cal and life sci­ence indus­try and it is now spe­cial­ized in devel­op­ing whole biotech­nol­o­gy pro­duc­tion process­es.

ARTES attends European Animal Health Investment Forum

ARTES will head for London’s elite May­fair dis­trict in Feb­ru­ary to take part in the ‘Drag­ons Den’ of vet­eri­nary med­i­cine, the Euro­pean Ani­mal Health Invest­ment Forum. This will be ARTES’ first par­tic­i­pa­tion in the high pres­tige invest­ment net­work­ing event. ARTES will be rep­re­sent­ed by its Man­ag­ing Direc­tor, Dr. Michael Pio­ntek, who will be talk­ing in par­tic­u­lar […]

ARTES and BioSun announce co-development for HPV vaccine

Lan­gen­feld, Ger­many / Tehran, Iran   ARTES Biotech­nol­o­gy and Bio­Sun Pharmed announced to join forces for the devel­op­ment and man­u­fac­tur­ing of a HPV (human papil­lo­ma virus) vac­cine in Iran. The agreed long-term col­lab­o­ra­tion involved the strength of both part­ners. ARTES Biotech­nol­o­gy GmbH (ARTES) is spe­cial­ized in cell line and process devel­op­ment of virus like par­ti­cle (VLP) […]

Sun Pharma & ICGEB sign exclusive deal on dengue vaccine — ARTES adds experience in VLP development and production

NEW DELHI, India I Octo­ber 19, 2016 Inter­na­tion­al Cen­tre for Genet­ic Engi­neer­ing and Biotech­nol­o­gy (ICGEB) and Sun Phar­ma today announced their new col­lab­o­ra­tion for devel­op­ment of a dengue vac­cine, tar­get­ed against all the four serotypes of Dengue virus that cause dis­ease in humans. ICGEB has devel­oped a tai­lored recom­bi­nant virus-like-par­ti­­cle (VLP) based tetrava­lent dengue vac­cine, […]